BioMmune Technologies Inc.
TSX VENTURE : IMU

March 05, 2015 09:30 ET

BioMmune Announces Anti-Cancer Activity Achieved by Restoring Immune Recognition and Killing of Tumour Cells

VANCOUVER, BRITISH COLUMBIA--(Marketwired - March 5, 2015) - BioMmune Technologies Inc. (TSX VENTURE:IMU), a company focused on harnessing the body's immune system to fight cancer and autoimmune diseases, has demonstrated in vivo, effective anti-cancer activity induced by new small molecule drugs that make cancer cells more visible to the immune system.

BioMmune has developed a complex screening program to identify novel chemicals that can make cancer cells visible to the cell-mediated arm of the immune system, normally responsible for anti-cancer immunity. The research utilizes a unique library of novel organic metabolites produced by marine organisms provided by Prof. Raymond Andersen, UBC Professor of Chemistry and Earth Ocean and Atmospheric Sciences. This library has previously yielded important new small molecule drugs.

As cancer cells transition from primary to metastatic they increasingly evolve mechanisms to hide from the immune system that normally detects and destroys cancer cells. The large number of metabolites from Dr. Andersen's marine library was screened by Prof. Wilfred Jefferies and his colleagues in UBC's Michael Smith Laboratory using a proprietary system to identify small molecule metabolites that increase the amount of "tumour antigens" on the cancer cell surface. These cells are now visible to the immune system, which attacks and kills them systemically, no matter where they are throughout the body.

"We have screened a large number of molecules from a library generated from marine sponges developed by Prof. Andersen. Several were identified for their ability to increase expression of proteins involved in the antigen processing pathway and in particular MHC I molecules that display the tumour antigens on the surface of cancer cells. One chemical structure resulted in the generation of a series of analogs by Prof. Andersen's group. One of these analogs has been tested for toxicity and anti-cancer activity on a lung carcinoma implanted into mice. The results indicate that this analog is not toxic and inhibits the growth of tumours in vivo. These data are very exciting and demonstrate that our new proprietary screening technology is able to detect and identify new lead anti-cancer agents," says Prof. Jefferies.

"The identification and discovery of new chemical entities that can increase the killing of cancer cells is a key milestone and is central for the application of new intellectual property, a valuable asset to the company. We will continue to accelerate this program to discover additional new structures that will be efficacious in the treatment of cancers," says Dr. Reinhard Gabathuler, President of BioMmune.

ABOUT BIOMMUNE

BioMmune Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, British Columbia, Canada. BioMmune is advancing three technologies developed at The University of British Columbia: 1. Utilizing proprietary screening systems for identifying novel compounds that are able to restore immune recognition and killing of cancer cells. 2. Exploiting the regulation of calcium channel activity which is very important for controlling cells involved in the immune system. By regulating these calcium channels, immune activity can be controlled in ways to improve their ability to combat cancers, infections and autoimmune diseases. 3. Modulating CD74, a protein involved in the immune system and its ability to fight foreign antigens. Finding molecules that regulate CD74 activity will aid the immune system to combat infections and cancers and to control autoimmune diseases. BioMmune trades on the TSX Venture Exchange under the symbol "IMU".

Forward Looking Statements

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may we may not be successful in either preclinical or clinical trials and not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors

Dr. Reinhard Gabathuler, President

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • BioMmune Technologies Inc.
    Dr. Reinhard Gabathuler
    President
    (514) 963-6177
    gaba@biommune.net